Drugs / Hesperetin
Hesperetin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06340087 | Mar → Sep 2024 | glucose metabolism disease | University of Vienna | Completed | No outcome recorded |
| Phase 0 | NCT05705596 | Jan → Jun 2023 | glucose metabolism disease | University of Vienna | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hesperetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06340087 ↗ |
| Known as | Eriodictyol 4'-monomethyl ether | ChEMBL registry synonym — accepted as the source's own label CHEMBL399121 ↗ |
| Known as | FEMA NO. 4313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL399121 ↗ |
| Known as | Hesperitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL399121 ↗ |
| Known as | NSC-57654 | ChEMBL registry synonym — accepted as the source's own label CHEMBL399121 ↗ |
| Modality | Small molecule | “the polyphenol hesperetin” NCT05705596 ↗ |